Loading...
Please wait, while we are loading the content...
Similar Documents
XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia
| Content Provider | Semantic Scholar |
|---|---|
| Author | Kim, Young‐ Hoon Shim, Jaemin Tsai, Chia‐ Ti Wang, Chun‐ Chieh Vilela, Gilbert C. Muengtaweepongsa, Sombat Kurniawan, Muchammad Taufik Maskon, Oteh Fern, Hsu Li Nguyen, Thang Huy Thanachartwet, Thititat Sim, Kenneth Camm, Alan John |
| Copyright Year | 2018 |
| Abstract | Background ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non-valvular atrial fibrillation (NVAF), with a favorable benefit-risk profile. XANAP investigated the safety and effectiveness of rivaroxaban in routine care in Asia-Pacific. Methods XANAP was a prospective, real-world, observational study in patients with NVAF newly starting rivaroxaban. Patients were followed at ~3-month intervals for 1 year, or for ≥30 days after permanent discontinuation. Primary outcomes were major bleeding events, adverse events (AEs), serious AEs and all-cause mortality; secondary outcomes included stroke/SE. Major outcomes were adjudicated centrally. Results XANAP enrolled 2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had received prior anticoagulation therapy. Co-morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior stroke/non-central nervous system SE/transient ischemic attack (32.8%) and myocardial infarction (3.8%). Mean CHADS2, CHA2DS2-VASc and HAS-BLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-years [95% confidence interval]) of treatment-emergent major bleeding, stroke and all-cause mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively. Persistence was 66.2% at the study end. Conclusions The real-world XANAP study demonstrated low rates of stroke and bleeding in rivaroxaban-treated patients with NVAF from Asia-Pacific. The results were consistent with the real-world XANTUS study and ROCKET AF. |
| Starting Page | 418 |
| Ending Page | 427 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| PubMed reference number | 30167013v1 |
| Alternate Webpage(s) | https://doi.org/10.1002/joa3.12073 |
| DOI | 10.1002/joa3.12073 |
| Journal | Journal of arrhythmia |
| Volume Number | 34 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse event Anticoagulation Therapy Atrial Fibrillation Cerebrovascular accident Confidence Intervals Cooley's anemia Diabetes Mellitus Embolism Heart Atrium Heart failure Hemorrhage Hypertensive disease Lupus Erythematosus, Systemic Morbidity - disease rate Myocardial Infarction Nervous system structure Patients Transient Ischemic Attack Warfarin rivaroxaban |
| Content Type | Text |
| Resource Type | Article |
